Arima Genomics

Gain unparalleled access to the 3D structure of the genome. Identify how spatial and temporal changes alter gene regulation and cellular function. #3DGenomics

[Arima Genomics @ArimaGenomics]

🧠 Unlock how the “dark genome” shapes the developing brain. Join our webinar next Thursday (hosted by @Xtalks) to see how Evf2, the first enhancer‑associated lncRNA, is rewriting what is known about genome architecture, interneuron development and neurodevelopmental disease risk.

📅 Save your spot: https://t.co/LtYtBrB2Gs

#3DGenomics #singlecell #Neuro

[Arima Genomics @ArimaGenomics]

Tomorrow's the day! 🎉 We’re kicking off #chromatin2025 at 9:30 AM EST w/ @BiolaMJavierre, @CarrerasIJC, @Javierrelab, @KatieEYost, @Anders_S_Hansen, @kazu_maeshima, @NIG_idenken, @_AnthonySchmitt, & other great speakers!

If you haven’t registered yet, there’s still time: https://t.co/8QL8XmrjVw. See you soon! 🧬🔬

[Arima Genomics @ArimaGenomics]

We’re excited to announce the winner of our first-ever Open Grant, as we extended applications to all research areas of genomics! 🧬

Congratulations to Varvara-Rigina Louma and the @anton_gh Lab at the @MDC_Berlin and @ChariteBerlin, who are pioneering research on how extrachromosomal DNA (#ecDNA) reintegration shapes cancer development and therapy resistance. Their lab tackles some of the toughest pediatric cancers, using cutting-edge 3D genomics to find new treatment possibilities.

Curious about their groundbreaking project? Read more in our latest blog: https://t.co/qiYzrczULq

[Arima Genomics @ArimaGenomics]

Unlock the secrets of the cancer genome! 🔬 Join us for a live webinar with UCSD’s Dr. Vineet Bafna as we explore how advanced #3DGenomics and ec3D technology reveal the hidden roles of extrachromosomal DNA in tumor evolution and therapy resistance. Don’t miss out on insights that could pave the way for next-generation cancer research and precision medicine. #ecDNA

Save your spot: https://t.co/ewBRAkjdqf

[Arima Genomics @ArimaGenomics]

Are you attending AMP 2025 this week? If so, be sure to check out the presentation on Saturday by our SVP of Science Anthony Schmitt of new data demonstrating the power of our Aventa™ Lymphoma test to clarify lymphoma diagnosis and serve as a novel approach for fusion and rearrangement detection in B- and T-cell lymphomas.

Learn more about our presentation and other upcoming date here: https://t.co/mHdcFTyCvi

#AMPath2025

[Arima Genomics @ArimaGenomics]

GenomeWeb highlighted how Arima Genomics is pioneering the use of 3D genomics to advance cancer diagnostics — with our Aventa Lymphoma test showing strong potential to replace traditional FISH-based tests for fusions and rearrangements.

As our CEO Tom Willis, PhD shared:
“Down the road, we definitely see this as a replacement for FISH because we can routinely perform a complete genome analysis of all the rearrangements in a tumor…as opposed to having to make hypothesis-driven choices about which diagnostic suspicions are leading to which FISH panels.”

We believe this innovation represents a major step forward for precision oncology and the future of clinical genomics. Thanks to Greg Cima and GenomeWeb for the thoughtful article showcasing our technology.

Read the full GenomeWeb's 360Dx article here - https://t.co/ecKXGhqKKK

#ArimaGenomics #3DGenomics #AventaLymphoma

[Arima Genomics @ArimaGenomics]

We can’t wait to see you in Boston at the AMP 2025 Annual Meeting & Expo!

Visit Arima Genomics at Booth #420 to learn how Aventa Lymphoma can help your patients and don't miss our Corporate Workshop on Wednesday 11/12 at 1pm!

Learn more, let us know you're coming and/or schedule some time to talk with our team: https://t.co/xGz6Ygje4x

#AMPath2025

[Arima Genomics @ArimaGenomics]

We have become aware of an ongoing scam in which individuals are impersonating Arima Genomics and offering fraudulent job opportunities, including fake job offers and requests for personal information.

Please be aware:
- Official job postings from Arima Genomics are only listed on our official LinkedIn page and on our company website.
- Arima Genomics will never request sensitive personal details (such as social security numbers or banking information) via unofficial channels or prior to a formal interview process.
- Emails from Arima Genomics will always come from our official domain: @arimagenomics.com. Any communication from other domains, such as @arimagenomics.us, is not legitimate.

If you have been contacted regarding a job opportunity and are unsure of its legitimacy, please contact us directly through our official website or LinkedIn page.

Your security is important to us. Thank you for helping us stay vigilant and alerting us to these incidents.

[Arima Genomics @ArimaGenomics]

How do we link distant genetic variants hidden in the genome’s “dark matter” to the mechanisms driving arthritis?

Join us Thursday to find out in our next #3DGenomics webinar, featuring the return of Dr. @G_Orozco_C from @OfficialUoM! She’ll share how spatial genome biology is uncovering connections between non-coding DNA and gene regulation—illuminating new paths toward understanding and treating complex diseases.

Register: https://t.co/mJtR7u2VJV

[Arima Genomics @ArimaGenomics]

pharmaphorum's Jonah Comstock featured our CEO, Tom Willis, PhD, in coverage of the LSX USA Congress panel, “What’s holding back precision medicine outside oncology.”

Tom joined industry leaders to explore how genomics innovation, data, and collaboration can help close the gap between scientific discovery and clinical adoption - and ultimately expand the reach of precision medicine beyond oncology.

The article captures the shared commitment across the biotech community to advance precision medicine - a mission that continues to guide our work at Arima Genomics.

Read the full article here: https://t.co/EFFmsR3Pkt

#ArimaGenomics #PrecisionMedicine #Genomics #LSXUSA

[Arima Genomics @ArimaGenomics]

Excited to share the news! The Arima Genomics Open Grant Program is now accepting proposals from researchers across ALL genomic fields. Whether you’re pioneering advances in genome assembly, single-cell analysis, human health and disease, or beyond, this opportunity is for you.

Applicants at any career stage - new to 3D genomics or seasoned experts - are welcome. Winner(s) will receive up to $10,000 in Arima kits or services, plus dedicated technical support for your project.

Deadline is Friday, November 7, 2025. Let’s push the boundaries of genomics together.

Learn more and apply: https://t.co/bTT4DQEQbl

[Arima Genomics @ArimaGenomics]

A new study from investigators at The Johns Hopkins University demonstrates the ability of our Aventa™ Lymphoma test to turn ambiguous FISH results into clear clinical answers for patients with diffuse large B-cell lymphoma (DLBCL).

Published in a special issue of the peer-reviewed scientific journal Genes, the study revealed that Aventa Lymphoma confirmed all typical FISH results while also clarifying every ambiguous case, uncovering additional genomic insights to help refine diagnoses and guide care decisions.

We’re proud of this additional validation of Aventa’s ability to provide the complete genomic picture in a single assay, helping clinicians bring greater diagnostic confidence to lymphoma care.

Read the full release here: https://t.co/20IAlMIaaM

#ArimaGenomics #AventaTest #LymphomaResearch #BCellLymphoma #Genomics #CancerDiagnostics #PrecisionMedicine #DLBCL #OncologyInnovation

[Arima Genomics @ArimaGenomics]

It's back! Registration is NOW OPEN for the 6th Annual Meeting on Advances in Nuclear Topology & 3D Chromatin Architecture in Cancer. Don’t miss insights from leading experts in the field. Join us online November 25th.

Register for free: https://t.co/ZBRMMyheFO #chromatin2025

@@_AnthonySchmitt

[Arima Genomics @ArimaGenomics]

What an incredible few days at #ASHG2025! We had a great turnout at our CoLab session yesterday, where Dr. Biswanath Chowdhury from the New York Genome Center joined us to reveal 3D insights into extrachromosomal DNA in cancer. The buzz around ecDNA and its potential to uncover new cancer vulnerabilities and “druggable” targets was inspiring - thanks to everyone who stopped by.

Its the last day, so stop by and chat with our team about how #3DGenomics is shaping precision medicine. Let’s keep the conversation going!

https://t.co/NiPLjyuDlx

[Arima Genomics @ArimaGenomics]

We will be at #ASHG2025! Here's where to find us if you're attending:

Booth: #2574
CoLab Talk: Oct. 16 | 4:00 PM | CoLab Theater 2

Stop by our booth to hear about our latest innovations and join our CoLab to hear how advanced #3DGenomics approaches are unlocking structural detail and functional insights into ecDNA in cancer.

Let's connect: https://t.co/7ssGVQSBnY

[Arima Genomics @ArimaGenomics]

Arima Genomics is thrilled to be attending the 2025 ABRF/SC3 Meeting in Dallas! We look forward to a fantastic meeting and meaningful conversations with the Core community. Supporting Core facilities is a priority for our team, and we’re excited about exploring opportunities to host educational trainings and fun lunch-and-learns together.

If you’re at the meeting, connect with Brenda from our team - let’s work together to advance genomics and build community!

#ABRF2025 #SC32025 @MyABRF

[Arima Genomics @ArimaGenomics]

New on the blog: Discover how the ec3D algorithm reconstructs cancer's extrachromosomal DNA (ecDNA) in 3D! This innovative approach unlocks insights into tumor biology, gene regulation, and therapy resistance. Dive into the future of cancer genomics: https://t.co/pj518FxRZu

[Arima Genomics @ArimaGenomics]

Earlier this month at #SOHO25, the annual meeting of the Society of Hematologic Oncology, we announced the broad commercial launch of the Aventa™ Lymphoma test, expanding access to a novel genomic approach for fusion and rearrangement detection in B- and T-cell lymphomas.

We’re honored that SOHO Insider covered this milestone, underscoring how we're helping bring greater diagnostic clarity to clinicians and patients facing lymphoma. This recognition highlights the growing role of advanced genomic tools in shaping the future of lymphoma care.

Read the full article here: https://t.co/JudwRYgDr8

[Arima Genomics @ArimaGenomics]

Fantastic energy at LSX USA Congress last week, where the biotech community came together to discuss the future of genomics, data, and drug development.

Our CEO, Tom Willis, PhD, joined the panel “AI, Data, and Precision Medicine: Opportunities, Challenges & Overcoming the Barriers to Personalised Medicine”, contributing insights on how to accelerate the impact of genomics in healthcare.

As Tom noted during the panel, “From an early signal in a clinical trial to a reimbursed, broadly adopted test - there’s a chasm of time and effort. What helps bridge that is having a test that is biologically interpretable. That’s something clinicians can learn and adopt as opposed to a completely new ‘black box’ discovery.”

We’re proud to be part of these conversations and to see Arima represented on stage as leaders discuss the future of precision medicine.

#ArimaGenomics #LSX #PrecisionMedicine #Genomics #Biotech

[Jane Skok @jane_skok]

Speaker Spotlight: Don’t miss @Anders_S_Hansen from MIT as he unpacks the secrets of distal gene regulation in space and time! Learn how enhancers find and activate their target genes—revealing new insights into the selectivity and dynamics of gene control. Reserve your seat: